Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Can-Fite BioPharma Ltd. (CANF) has a Wall Street consensus price target of $7.25, based on estimates from 4 covering analysts. With the stock currently trading at $4.75, this represents a potential upside of +52.6%. The company has a market capitalization of $14.17B.
Analyst price targets range from a low of $4.50 to a high of $10.00, representing a 76% spread in expectations. The median target of $7.25 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CANF trades at a trailing P/E of -4.4x. Analysts expect EPS to grow -273.8% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CANF stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CANF is $7.25, representing 52.6% upside from the current price of $4.75. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CANF has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $7.25 implies 52.6% upside from current levels.
CANF's current price is $4.75 with a consensus target of $7.25 (52.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for CANF, while the most conservative target is $4.5. The consensus of $7.25 represents the median expectation. These targets typically reflect 12-month expectations.
CANF is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CANF stock forecast based on 4 Wall Street analysts shows a consensus price target of $7.25, with estimates ranging from $4.5 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CANF, with a "Buy" consensus rating and $7.25 price target (52.6% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CANF analyst price targets range from $4.5 to $10, a 76% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.25 consensus represents the middle ground.